Aurion Biotech begins dosing patients in phase 3 trial for corneal therapy

April 8, 2026 7:00 AM

Aurion Biotech has started dosing the first patients in its ASTRA Phase 3 study evaluating AURN001, an investigational cell therapy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found